XML 25 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Cash flows from operating activities:      
Net loss $ (18,744,000) $ (37,368,000) $ (26,177,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 1,093,000 779,000 1,630,000
Amortization of deferred financing costs and debt discount 979,000 1,220,000 893,000
Joint Venture acquisition obligation accretion 365,000 579,000 204,000
Provision for doubtful accounts (105,000) 1,084,000 1,141,000
Provision for expired enzyme 0 313,000 0
Change in fair value of warrants (7,668,000) (369,000) (418,000)
Change in fair value of option liability 0 0 (2,250,000)
Stock-based compensation 2,041,000 3,101,000 3,608,000
Equity loss from investment in joint venture 0 0 48,000
Gain (loss) on asset disposal 8,000 (33,000) 257,000
Gain on previously held equity interest in joint venture 0 0 (4,892,000)
Gain on sale of assets 0 0 (4,453,000)
Loss on debt extinguishment 260,000 0 708,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:      
Accounts receivable 328,000 2,057,000 (1,209,000)
Inventories 490,000 (815,000) (459,000)
Other current assets (637,000) 510,000 (24,000)
Other assets 363,000 11,000 (854,000)
Accounts payable and accrued expenses 1,045,000 (1,147,000) (409,000)
Deferred revenues, related party 0 0 (638,000)
Deferred revenues 3,000 (100,000) (1,223,000)
Long-term deferred rent (289,000) (152,000) (46,000)
Net cash used in operating activities (20,468,000) (30,330,000) (34,563,000)
Cash flows from investing activities:      
Purchases of property and equipment (611,000) (764,000) (519,000)
Expenditures for intellectual property (13,000) (255,000) 0
Proceeds from sale of assets 11,000 76,000 5,000,000
License agreement termination fee 0 (400,000) (800,000)
Cash acquired in purchase of the Joint Venture 0 0 5,000
Net cash (used in) provided by investing activities (613,000) (1,343,000) 3,686,000
Cash flows from financing activities:      
Principal payments on long-term obligations (25,032,000) (1,962,000) (22,304,000)
Proceeds from long-term obligations 17,700,000 0 27,000,000
Debt issuance costs and loan fees (1,854,000) 0 (1,744,000)
Joint venture purchase payments (1,623,000) (2,262,000) (221,000)
Proceeds from exercise of employee stock options and warrants and stock purchase plan 4,997,000 4,151,000 225,000
Proceeds from sale of common stock 29,054,000 19,001,000 18,000,000
Proceeds from issuance of preferred stock 0 13,500,000 0
Costs from sale of common stock (2,370,000) (425,000) (184,000)
Costs from sale of preferred stock 0 (1,129,000) 0
Dividends paid on preferred stock (75,000) 0 0
Net cash provided by financing activities 20,797,000 30,874,000 20,772,000
Effect of exchange rate changes on cash and cash equivalents 0 (85,000) (106,000)
Net decrease in cash and cash equivalents (284,000) (884,000) (10,211,000)
Cash and cash equivalents at beginning of year 14,622,000 15,506,000 25,717,000
Cash and cash equivalents at end of year 14,338,000 14,622,000 15,506,000
Cash paid during period for:      
Interest 1,994,000 2,588,000 2,252,000
Final payment fee on long-term debt 1,839,000 0 1,078,000
Supplemental schedule of non-cash investing and financing activities:      
Conversion of preferred stock into common stock 10,000 16,000 0
Declared dividend related to preferred stock 3,000 72,000 0
Fair value of warrants allocated to additional paid-in capital 776,000 0 949,000
Fair value of intangible assets acquired 0 0 9,394,000
Fair value of tangible assets acquired 0 0 260,000
Joint venture purchase obligation 0 0 4,709,000
Fair value of previously held equity interest at acquisition date $ 0 $ 0 $ 4,928,000